Project Stories help illustrate how Teijin Pharma takes a unique
approach to developing new treatments.

Special Edition

June 17, 2018 marked 100 years since the founding of Teijin. With healthcare as a core pillar of the Teijin Group’s operation, Teijin Pharma have played a key role so far in the history of Teijin. Read on to find out more.

Read More

Pharmaceutical Business / Cardiovascular and Metabolic Diseases

Teijin Pharma realizes the importance of choice for patients. When it comes to treatments, patients benefit from a range of options to suit their personal circumstances. In the case of Acromegaly, Teijin Pharma saw how they could improve patients’ quality of life through Somatuline subcutaneous injection.

Read More

Home Healthcare Business / Respiratory Diseases

Home Oxygen Therapy (HOT) was a major part of the forming chapter of the Teijin Pharma story, as explored in Project Story Vol. 6. But the development of Teijin’s first membrane-type oxygen concentrator and its subsequent release in 1982 is only half the story. Teijin’s HOT technology has gone on growing and evolving alongside the business that supports it.

Read More

Home Healthcare Business / Respiratory Diseases

Dedicated to pioneering medical solutions, Teijin Pharma began business with the
same commitment to taking on new challenges which they have to this day. The
ability to recognize the needs of the healthcare industry and commit to the right
solutions has defined the company from day one.

Read More

Vol. 5
Update: March 31, 2017

How Teijin Pharma Is Changing the Future of Pharmaceutical Manufacturing
Creating Products to Match Medical Needs

Pharmaceutical Business / Respiratory Diseases

In line with their philosophy to Enhance Quality of Life, Teijin Pharma has launched a new 45 mg reduced-size tablet form of their proprietary expectorant drug. Read on to find out how this small modification will greatly change the way patients of respiratory diseases are treated.

Read More

Home Healthcare Business /
Respiratory Diseases

Sleep Apnea Syndrome (SAS) is a modern disorder that is estimated to affect more than 3 million people in Japan. Learn how Teijin utilized its home healthcare business expertise and insights to develop SLEEPMATE, an innovative device that treats SAS.

Read More

Building a Strong Platform in the Field of Bone and Joint Diseases

Pharmaceutical Business /
Bone and Joint Diseases

Teijin Pharma are always looking ahead. Since they first foresaw the importance of treating osteoporosis in the 1980s, Teijin Pharma have challenged development of everything from simple diagnostic tools to a wide range of treatments in the field of bone and joint diseases.

Read More

Providing Home Healthcare Support in a Disaster

Home Healthcare Business / Respiratory Diseases

From the moment the earthquake struck, Teijin Pharma members moved swiftly and diligently to supply oxygen cylinders to affected patients.

Read More

Vol. 1
Update: March 31, 2017

A New Drug Born from R&D

Pharmaceutical Business / Cardiovascular and Metabolic Diseases

Teijin Pharma has three target categories within the world of healthcare, bone and joint diseases, respiratory diseases and cardiovascular and metabolic diseases. This is the story of a new drug which helped us to grow in the cardiovascular and metabolic diseases’ field, improving quality of life for patients.

Read More